Effect of dutasteride on androgen-response gene expression during the tumor regrowth phase of intermittent androgen ablation therapy in patients with advanced prostate cancer.

Trial Profile

Effect of dutasteride on androgen-response gene expression during the tumor regrowth phase of intermittent androgen ablation therapy in patients with advanced prostate cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2014

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Prostate cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.
    • 24 Jan 2013 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center record: NU-E08U1).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top